Ishimura Norihisa, Yamasawa Kunihiro, Karim Rumi Mohammad Azharul, Kadowaki Yasunori, Ishihara Shunji, Amano Yuji, Nio Yoshinori, Higami Tetsuya, Kinoshita Yoshikazu
Second Department of Internal Medicine, Shimane Medical University, 89-1 Enya-cho, Izumo-shi, Shimane 693-8501, Japan.
Cancer Lett. 2003 Sep 25;199(2):169-73. doi: 10.1016/s0304-3835(03)00384-7.
We investigated the frequency of BRAF mutations in human pancreatic cancer specimens to determine its role in the development of pancreatic cancer. Nine pancreatic cancer samples without a K-ras codon 12 mutation and 19 with a K-ras mutation were included in the study. Analyses of the BRAF sequence revealed mutations in exon 15 (V599E) in two cases, both of which also exhibited a K-ras codon 12 mutation. No BRAF mutation was found in cases without a K-ras mutation. The BRAF V599E mutation was not found to be a major mutation in pancreatic cancers that had no K-ras codon 12 mutation.
我们研究了人类胰腺癌标本中BRAF突变的频率，以确定其在胰腺癌发生中的作用。该研究纳入了9个无K-ras密码子12突变的胰腺癌样本和19个有K-ras突变的样本。BRAF序列分析显示，有2例在第15外显子（V599E）发生了突变，这2例也都存在K-ras密码子12突变。在无K-ras突变的病例中未发现BRAF突变。在无K-ras密码子12突变的胰腺癌中，未发现BRAF V599E突变是主要突变。
